- Home
- ROIV vs ACHC Comparison
ROIV vs ACHC Comparison
Compare ROIV & ACHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- ACHC
- Stock Information
- Founded
- ROIV 2014
- ACHC 2005
- Country
- ROIV United Kingdom
- ACHC United States
- Employees
- ROIV N/A
- ACHC N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- ACHC Medical Specialities
- Sector
- ROIV Health Care
- ACHC Health Care
- Exchange
- ROIV Nasdaq
- ACHC Nasdaq
- Market Cap
- ROIV 8.4B
- ACHC 2.1B
- IPO Year
- ROIV N/A
- ACHC N/A
- Fundamental
- Price
- ROIV $10.80
- ACHC $27.71
- Analyst Decision
- ROIV Buy
- ACHC Strong Buy
- Analyst Count
- ROIV 4
- ACHC 10
- Target Price
- ROIV $17.50
- ACHC $54.45
- AVG Volume (30 Days)
- ROIV 6.2M
- ACHC 3.2M
- Earning Date
- ROIV 05-29-2025
- ACHC 05-12-2025
- Dividend Yield
- ROIV N/A
- ACHC N/A
- EPS Growth
- ROIV N/A
- ACHC N/A
- EPS
- ROIV N/A
- ACHC 2.78
- Revenue
- ROIV $122,585,000.00
- ACHC $3,153,963,000.00
- Revenue This Year
- ROIV N/A
- ACHC $7.90
- Revenue Next Year
- ROIV N/A
- ACHC $8.58
- P/E Ratio
- ROIV N/A
- ACHC $9.29
- Revenue Growth
- ROIV 140.04
- ACHC 7.69
- 52 Week Low
- ROIV $8.73
- ACHC $20.36
- 52 Week High
- ROIV $13.06
- ACHC $82.41
- Technical
- Relative Strength Index (RSI)
- ROIV 50.90
- ACHC 60.39
- Support Level
- ROIV $10.58
- ACHC $23.83
- Resistance Level
- ROIV $11.77
- ACHC $24.77
- Average True Range (ATR)
- ROIV 0.34
- ACHC 1.18
- MACD
- ROIV -0.05
- ACHC 0.75
- Stochastic Oscillator
- ROIV 23.11
- ACHC 89.65
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About ACHC Acadia Healthcare Company Inc.
Acadia Healthcare Co Inc acquires and develops behavioral healthcare facilities. Acute inpatient psychiatric facilities and specialty treatment facilities contribute the vast majority of Acadia's revenue in the United States. The company's revenue is derived from services rendered to patients for inpatient psychiatric and substance abuse care, outpatient psychiatric care, and adolescent residential treatment.